Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Shares Outstanding (2016 - 2026)

Cytosorbents filings provide 16 years of Shares Outstanding readings, the most recent being $62.8 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 14.54% to $62.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.8 million, a 14.54% increase, with the full-year FY2025 number at $62.8 million, up 14.54% from a year prior.
  • Shares Outstanding hit $62.8 million in Q4 2025 for Cytosorbents, roughly flat from $62.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $62.8 million in Q4 2025 to a low of $43.3 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $44.3 million (2023), compared with a mean of $50.2 million.
  • Biggest five-year swings in Shares Outstanding: rose 0.36% in 2022 and later grew 24.3% in 2023.
  • Cytosorbents' Shares Outstanding stood at $43.5 million in 2021, then grew by 0.36% to $43.6 million in 2022, then rose by 24.3% to $54.2 million in 2023, then grew by 1.09% to $54.8 million in 2024, then grew by 14.54% to $62.8 million in 2025.
  • The last three reported values for Shares Outstanding were $62.8 million (Q4 2025), $62.8 million (Q3 2025), and $62.6 million (Q2 2025) per Business Quant data.